Description
Summary Abstract
ARA-290 (Cibinetide; EPO helix-B surface peptide (HBSP)) is a synthetic 11-amino acid peptide derived from the helix-B surface domain of erythropoietin (EPO) — specifically a region that does not contact the classical homodimeric EPO receptor (EPOR). While conventional EPO activates the EPOR homodimer to drive erythropoiesis, ARA-290 selectively engages the Innate Repair Receptor (IRR), formed by the heterodimer of EPOR and the β-common chain (βc, CD131), expressed on neurons, immune cells, pancreatic beta cells, endothelial cells, and cardiac tissue with negligible erythroid progenitor expression. This receptor selectivity underlies ARA-290’s separation of tissue-protective and anti-inflammatory activity from all erythropoietic effects — confirmed across multiple species and Phase 2 human trials. ARA-290 holds FDA Orphan Drug Designation and Fast Track status for small fiber neuropathy (SFN) associated with sarcoidosis; the DOLOR Phase 2b trial produced a 23% increase in corneal nerve fiber density (CNFD) versus placebo as the primary endpoint.
Clinical Indications
ARA-290 has been evaluated in small fiber neuropathy, metabolic disease, and inflammatory conditions across multiple Phase 2 programs:
- Small Fiber Neuropathy (SFN) — DOLOR Phase 2b: 4 mg/day SC × 28 days in sarcoidosis-associated SFN produced a 23% increase in corneal nerve fiber density (CNFD) versus placebo; secondary endpoints (SFNSL symptom scores, 6-minute walk test) also favored ARA-290.
- Type 2 Diabetes & Metabolic Research: Phase 2 in T2D improved HbA1c, lipid profiles, and significantly reduced neuropathic pain scores (PainDetect); pancreatic beta cell IRR expression supports investigation of direct beta cell cytoprotective effects.
- Stroke Neuroprotection: ARA-290 does not increase hemorrhagic transformation risk with rtPA — unlike conventional EPO at thrombolytic doses — supporting investigation as a neuroprotective adjunct in ischemic stroke research.
- Inflammatory Disease: IRR expression in macrophages, dendritic cells, and endothelial cells supports research in conditions characterized by innate immune dysregulation and chronic inflammation.
- Cardiac & Ischemic Tissue Protection: IRR expression in cardiomyocytes and the STAT3/Bcl-2 anti-apoptotic axis support investigation in ischemia-reperfusion injury models.
Contraindications
- Active Malignancy: ARA-290 activates the JAK2/STAT3 pathway — a survival and proliferation pathway constitutively active in several lymphomas, leukemias, and solid tumors; all published Phase 2 protocols excluded patients with active malignancy as an absolute contraindication.
- Rapid IV Infusion: The IV half-life of ARA-290 is approximately 1.1–2.3 minutes; while IV administration is used in research, the extremely short systemic exposure requires careful dose management and does not support routine IV clinical delivery.
- Pending Phase 3 Regulatory Status: ARA-290 remains investigational (not FDA-approved); Phase 3 advancement for SFN/sarcoidosis has been delayed pending additional funding; clinical use outside approved trials requires appropriate investigational framework.
Mechanism of Action (MOA)
ARA-290 functions as a “hit-and-run” IRR agonist — its short half-life limits sustained receptor engagement while triggering downstream cascades that persist beyond peptide clearance:
IRR Engagement → JAK2/STAT3 & Anti-Apoptosis
ARA-290 engages the Innate Repair Receptor (EPOR–βc heterodimer) on neurons, immune cells, and beta cells — not the EPOR homodimer. IRR activation phosphorylates JAK2, which drives STAT3 nuclear translocation and transcription of anti-apoptotic genes (Bcl-2, Bcl-xL, Mcl-1). No erythroid progenitor engagement occurs; hemoglobin, hematocrit, and reticulocyte count remain unchanged across all Phase 2 human trial doses.
NF-κB Suppression & Anti-Inflammation
ARA-290 inhibits NF-κB nuclear translocation, reducing transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and endothelial adhesion molecule cascades. This mechanism is operative in macrophages, endothelial cells, and neural tissue, contributing to the systemic anti-inflammatory activity observed in metabolic and neuropathic research contexts.
TRPV1 Antagonism & Nerve Regeneration
ARA-290 directly modulates TRPV1 (transient receptor potential vanilloid 1) nociceptive channels in peripheral sensory neurons, reducing pain signal transmission independently of the JAK2/STAT3 pathway. Structural small fiber regeneration — evidenced by the 23% CNFD increase in the DOLOR trial — reduces the peripheral pain substrate itself over time, providing mechanistically distinct analgesia from central analgesics.
Key Features & Specifications
ARA-290 is the only IRR-selective EPO-derived peptide with Phase 2 clinical data across neuropathic and metabolic indications:
Chemical Analysis
| Property | Specification Reference Data |
|---|---|
| Sequence | 11-AA EPO helix-B surface peptide (derived from EPO AA 11–15, 58–65 non-contact surface region) |
| CAS Number | 1234361-73-9 (confirm against CoA) |
| Molecular Weight | ~1,266 Da |
| PubChem CID | Not established |
| Synonyms | Cibinetide; ARA-290; EPO helix-B surface peptide (HBSP) |
| Form / Variation | 10 MG Lyophilized (P-018) |
Storage, Safety, and Handling
Storage Protocol
Store lyophilized ARA-290 at −20°C, protected from light and moisture; lyophilized form is stable for 24 months under nitrogen atmosphere. Reconstituted solution should be used within 24–48 hours and stored at 2–8°C; do not freeze after reconstitution. Reconstitute with sterile water for injection or bacteriostatic water using gentle agitation — do not vortex. As a short 11-AA peptide, ARA-290 is subject to proteolytic degradation if improperly stored; maintain the cold chain from storage to use.
Handling & Compliance
Prepare reconstituted solutions under sterile technique with gloves and appropriate PPE. ARA-290 has been well-tolerated across Phase 2 sarcoidosis and T2D programs with no dose-limiting toxicities reported; immunogenicity (antibody formation) has not been a reported concern. It remains investigational and is not FDA-approved as a drug. Active malignancy is an absolute contraindication in all published trial protocols due to JAK2/STAT3 pro-survival signaling. The non-erythropoietic profile means no hematological monitoring for polycythemia is required, distinguishing it from conventional EPO derivatives.